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Abstract
This paper aims to identify problems in estimating and the interpretation of the magnitude of intervention-related change over time
or responsiveness assessed with health outcome measures. Responsiveness is a problematic construct and there is no consensus on
how to quantify the appropriate index to estimate change over time between baseline and post-test designs. This paper gives an
overview of several responsiveness indices. Thresholds for effect size (or responsiveness index) interpretation were introduced some
thirty years ago by Cohen who standardised the difference-scores (d) with the pooled standard deviation (dySD ). However, pooled
many effect sizes (ES) have been introduced since Cohen’s original work and in the formula of one of these ES, the mean change
scores are standardised with the SD of those change scores (dySD ). When health outcome questionnaires are used, this effect change
size is applied on a wide scale and is represented as the Standardized Response Mean (SRM). However, its interpretation is
problematic when it is used as an estimate of magnitude of change over time and interpreted with the thresholds, set by Cohen for
effect size (ES) which is based on SD . Thus, in the case of using the SRM, application of these well-known cut-off points for pooled
pooled standard deviation units namely: ‘trivial’ (ES-0.20), ‘small’ (ESG0.20-0.50), ‘moderate’ (ESG0.50-0.80), or large
(ESG0.80), may lead to over- or underestimation of the magnitude of intervention-related change over time due to the correlation
between baseline and outcome assessments.
Consequently, taking Cohen’s thresholds for granted for every version of effect size indices as estimates of intervention-related
magnitude of change, may lead to over- or underestimation of this magnitude of intervention-related change over time.
For those researchers who use Cohen’s thresholds for SRM interpretation, this paper demonstrates a simple method to avoid over- or
underestimation.
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Introduction
Methodological problems in estimating change in out-
come with well-known measures of quality of life or
health status have become a significant place on the
research agenda in clinical evaluation research. How-
ever, these methodological problems seem to be rele-
vant in integrated care research in which the integrat-
ed approach is compared with standard care practice
when quality of life or health status outcome measures
are used. Furthermore, improving methods to estimate
change may contribute in the development of evidence
based practice. This article was written because
researchers in the field of health services research
seem often unaware of the wide variety of indices that
may contribute to the understanding of an interven-
tion’s or programme’s effect (in addition to its statisti-
cal significance) in terms of health-related Quality of
Life (HRQL) outcome or health-related functional stat-
us (HRFS). In the attempts to improve healthcare
delivery with a new approach, researchers may have
the need to distinguish between those who improved
in terms of ‘small’, ‘moderate’ or ‘large’ before this new
approach will become general practice. The problemInternational Journal of Integrated Care – Vol. 2, 17 December 2002 – ISSN 1568-4156 – http://www.ijic.org/
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of testing differences between the new approach-
group and a standard care group goes together with
the dilemma that with large samples, trivial differences
between these groups may be statistically significant.
There is a growing recognition that assessing an
intervention’s effect should not only focus at the sta-
tistical significance of the differences in health out-
come between the experimental care and control
group, but should also focus at the relevance or
importance of these outcomes. Estimating the magni-
tude of the difference between change scores in both
groups, the difference between mean change scores
are expressed in standard deviation units with the
effect size index (ES). To compare the magnitude of
change D assessed in the experimental group with E
change D assessed in the control group the idea of C
effect size between groups can be turned on its side
and applied to measurement instruments to estimate
the amount of change over time within a group.
Change over time indices are also applied to meas-
urement instruments to evaluate them in terms of
being sensitive to detect change in before—after stud-
ies. In literature on psychometrics or clinimetrics the
concept of responsiveness was introduced to denote
the magnitude of change over time or sensitivity to
change over time. However, many responsiveness
indicators have been proposed and resulted in numer-
ous effect size indices (ES). Most of the indicators
agree on the numerator (the change score between
baseline and post-treatment) but there is little agree-
ment on the appropriate denominator. Since a general
convention for effect size interpretation is used for
almost any ES out of this effect size family, research-
ers run the risk of overestimation or underestimation
of an intervention’s effect. This paper gives, on the
one hand, an overview (not an exhaustive enumera-
tion) of several responsiveness indices that may be
relevant for evaluation research in health care. On the
other hand, this paper gives a simple solution for
underestimation or overestimation for two widely used
ES.
Health services research is heavily dependent on valid
health measures e.g. of health-related quality of life
(HRQL) or health-related functional status (HRFS).
These concepts have become important in the meas-
urement of intervention-outcome and used as com-
parable outcomes in cost-effectiveness evaluation.
However, in evaluation studies quality of life outcomes
have turned out to be a ‘kaleidoscopic’ concept since
no consensus exists with regard to the meaning of
the concept in either the research community or the
clinical community. Furthermore, the operationaliza-
tion of the concept of (health-related) quality of life is
heavily dependent on the disciplinary perspective in
outcome assessment. This lack of consensus has
given rise to the development of a myriad of measures
involving different components whose conceptual
dimensions vary w1x. Therefore, instruments labelled
as quality of life measures ‘‘may appear as health
status, physical functioning, emotional functioning,
perceived health status, symptoms, mood, need sat-
isfaction, well being, and, often, several of these at
the same time’’ w2x. During the last 10 to 15 years,
there has been an exponential increase in the devel-
opment and use of instruments to measure the out-
comes of medical interventions from the patient’s
perspective. A family of more than 150 instruments
were identified in 75 studies w3x; in 1996, Spilker et
al. catalogued nearly 215 measures in their second
edition of ‘‘Quality of Life and Pharmacoeconomics in
Clinical Trials’’ w4x. Since there is no consensus on
the theoretical construct of quality of life w2, 5–8x, the
universe of domains belonging to this concept (and
therefore the ongoing discussion on the selection of
items by which it is operationalized), we prefer con-
cepts such as health-related functional status. Func-
tional status reflects the ability to perform the tasks of
daily life in physical, emotional and social domains.
There is also a growing agreement on the compo-
nents of these constructs and the validity of their
measurement; for example, by validating these self-
report measures with evidence-based measures w9–
11x. By using the term health-related functional status
(HRFS) in this paper, we implicitly assume that a
change in health status or functioning is indirectly
related to the patient’s subjective experience of quality
of life.
For health care administrators or other health profes-
sionals who feel the need to measure HRFS as an
outcome in evaluation of, for example, the effective-
ness of hip-replacement by comparing integrated care
with standard care w12x, it is essential to know that
the choice of available health status instruments is
related to the methodological debate on the psycho-
metric properties of instruments (in contrast to out-
comes such as physiologic measures). Consequently,
this choice is also associated with methodological
issues relating to the interpretation of outcome in
terms of the magnitude of intervention-related change
over time in HRFS or the assessment of the magni-
tude of differences in outcome between experimental
(e.g. managed care, transmural care, shared care)
and control groups (standard care, usual care).
Because improving the functional status of patients
has become a central therapeutic goal of treatment
for many diseases, it is important that health admin-
istrators, clinicians and researchers develop a com-
mon understanding of:International Journal of Integrated Care – Vol. 2, 17 December 2002 – ISSN 1568-4156 – http://www.ijic.org/
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– what HRFS concepts mean;
– which measure is likely to be the most appropriate
one in the context of the disease and the evalua-
tion of, for example, an interdisciplinary or inte-
grated approach;
– the methods to assess intervention-related change
(responsiveness of outcome measures); and
– the methods by which a valid interpretation of the
magnitude of that change in terms of relevance or
importance can be achieved.
In the current paper, the methods to assess the
effectiveness of an intervention in terms of change
over time (responsiveness) will be discussed since
valid assessment of the magnitude of the patients’
improvement, deterioration and of no change seems
to become important in detecting stable, improved and
deteriorated patients-groups to evaluate direct
costs of new interventions in the context of disease
management.
The psychometric properties of
HRFS outcome measurement
tools
When the reliability and validity of health-related func-
tioning measures have been established, these psy-
chometric properties are generally accepted condi-
tions for use of these measures in evaluation research.
However, the appropriateness of the instrument
designed to measure change over time in persons is
not only determined by its reliability and validity.
Measuring change in order to evaluate efficacy of, for
example, new care interventions requires the instru-
ment to be sensitive to detecting change when
patients improve in physical function after that inter-
vention. Over the last 15 years, this property has
become well known through the widely used concept
of responsiveness. Responsiveness of health status
measures has been denoted as one of the ‘holy trinity’
of necessary psychometric properties of health status
instruments: reliability, validity and responsiveness
although other researchers classify responsiveness as
longitudinal validity w13x. To quantify responsiveness,
several effect sizes are used as estimates of the
amount of change detected with an instrument. One
of the aims of this paper is to address some method-
ological issues relating to the assessment of change
over time in health-related functional status and the
meaning of the magnitude of this change in scores
within experimental and control groups. Traditionally,
the many generations of researchers who have eval-
uated the efficacy of care-related interventions, base
their decisions on the statistical significance of the
within-group (intervention-related) change over time
or any statistically significant difference in change from
repeated measurements between experimental (care)
and control groups (with the underlying hypothesis
that the experimental group should show a higher
mean change in terms of improvement compared to
the control group) w12, 14x. In some cases, investi-
gators eager for results are likely to detect a statisti-
cally significant (but very small) change in scores
related to the intervention, simply due to large sample
size. Consequently, even if change which is statisti-
cally significant, though trivial in magnitude, is detect-
ed, the p-0.05 doctrine unwittingly pushes the
question of how meaningful, important, relevant, or
substantial the change is into the background. Signif-
icance tests support the decision as to whether the
change is due to chance fluctuation or can be func-
tionally related to (medical) intervention. The observed
statistical significance does not indicate the magnitude
of change. In spite of this, some researchers implicitly
suggest that smaller p-values represent larger, and
thus more ‘relevant’, effects w15x.
Against this background, the objectives of this paper
can be formulated in terms of the following topics:
– Responsiveness is a construct that is used with
different theoretical definitions and with a wide
variety of operationalisations by effect size indices.
– How comparable are different operationalisations
of effect sizes (ES) when outcome is interpreted
as ‘trivial’ (ES-0.20), ‘small’ (ESG0.20-0.50),
‘moderate’ (ESG0.50-0.80), or ‘large’ (ES
G0.80) according to the well-known thresholds of
Cohen? w16x
– How concordant are the effect sizes, labelled by
the researcher as ‘trivial’, ‘small’, ‘moderate’, or as
‘large’ change in a domain of health-related func-
tion with the patient’s perception of change in the
same domain signified with the same qualitative
terms?
Responsiveness, a problematic
construct
To give greater meaning to the interpretation of the
amount of change in scores on health-related func-
tional status instruments, the concept of responsive-
ness was introduced in publications. For evaluation
studies, the usefulness of a HRFS- instrument dep-
ends on its ability to detect a change that is clinically
meaningful. Clinically meaningful refers to a change
that justifies alteration in management of the disease
or to a change that indicates the efficacy of an
innovative type of intervention in domains of HRFS.
Responsive measures discriminate between trivial andInternational Journal of Integrated Care – Vol. 2, 17 December 2002 – ISSN 1568-4156 – http://www.ijic.org/
4 This article is published in a peer reviewed section of the International Journal of Integrated Care
substantial changes within groups and consequently,
show the difference in change between those groups.
Thus, the term responsiveness is used as an indicator
of the instrument’s sensitivity to change, as well as
an indicator of the magnitude of intervention-related
change over time. The term responsiveness, however,
is a confusing one for the beginner who encounters
it in the literature, since papers addressing interven-
tion-related change in terms of HRFS may refer to a
varying composite of aspects. As appears from a
selection of scientific papers, the term responsiveness
is used as an operational definition of:
– ‘An indicator of the sensitivity of an instrument to
detect change over time’ w17–22x or even refer to
the extent to which a measure is sensitive to real
change w23x;
– ‘statistically significant change in an experimental
group in which change should be present’ w24x;
– ‘an indicator of the magnitude of treatment-related
change’ w20–22, 25–35, 35–56x;
– ‘a measure of clinically relevant change in health’
w57, 58x, although some investigators prefer the
term ‘clinically significant change’ w59, 60x.
Qualitative terms such as ‘clinically important’ need at
least a golden standard. However, such a standard is
not available for HRFS measures. An substitute that
is often used for a golden standard for HRFS is an
external criterion. The blinded observation of a health
professional can be used as an external criterion for
justifying the interpretation in terms of clinically rele-
vant or important change in HRFS. Another external
criterion or yardstick for the interpretation of changes
in HRFS is the patient’s perception of the importance
of change after (for example) a specific intervention.
Husted et al. w61x distinguished internal responsive-
ness from external responsiveness by defining internal
responsiveness as the ability of a measure to detect
change over time, whereas external responsiveness
was defined as the extent to which change in a
measure relates to corresponding change in a refer-
ence measure w11, 62, 63x. Despite this clarification
of the concept of responsiveness by this recently
published classification, the assessment of change in
HRFS over time in evaluation research is quantified
using a variety of approaches. For the sake of clarity,
we will therefore in this paper use the concepts in the
following meaning:
– responsiveness: the psychometric property of a
measurement instrument, namely its sensitivity to
detect difference between two points in time
(change over time) within groups;
– meaningful or relevant difference: the amount of
change in scores or the magnitude of change
within and between groups, according to statistical
or other quantitative criteria (e.g. effect size
indices);
– clinically relevant or clinically important change in
scores on a health-related functional status meas-
ure as the magnitude of change that is linked to
an external criterion of relevance.
The purpose of a study and its study design may
require different psychometric properties of the out-
come measure. Consequently, the measure must
either have the property of being able to detect differ-
ences between subjects at a single point in time
(discriminative instruments) i.e. the ability to differen-
tiate between groups ‘who have a better HRFS and
those who have a worse HRFS’ w53, 64, 65x. Other
studies may require the instrument’s ability to detect
change over time within subjects (evaluative instru-
ments) w66–68x. Consequently, in randomised clinical
trials (RCT) or quasi-experimental designs, HRFS-
instruments should have both properties, namely: 1.
the ability to reliably estimate change between base-
line and post-test within an experimental and a control
group, and 2. the ability to estimate the difference in
change over time by comparing the average change
assessed in e.g. patients receiving standard care and
in patients receiving the new care intervention in order
to determine intervention-related effect, when it is
hypothesised that subjects assigned to the care inno-
vation group are expected to change (on the average)
more than those in the control group do.
Responsiveness and the
instrument’s scope: generic
versus specific measures
An important criterion for choosing an instrument in
order to detect change in HRFS is its generic or
disease-specific scope, which will depend on the
objectives of the specific study. Generic health status
measures seek a broad perspective that is not speci-
fically related to the restricted scope of the HRFS of
a specific disease. Therefore, generic measures allow
investigators to compare health status across different
diseases and interventions w69x. Generic measures
are health-related to the extent that disease, injury,
treatment, intervention, or policy w70x influences them.
Disease-specific measures focus on the disease being
studied, allowing greater sensitivity to intervention-
related change compared to generic measures. The
responsiveness of a health status instrument is an
important issue in the decision to use disease-specific
or generic measures of health-related functional state.International Journal of Integrated Care – Vol. 2, 17 December 2002 – ISSN 1568-4156 – http://www.ijic.org/
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For example, for those cases in which therapeutic
effects are likely to be modest and undramatic w12,
19, 71x, a better sensitivity to change over time of an
instrument is a necessary condition. In health services
research, hypothesising statistically significant change
over time and more substantial change (improvement)
in patients assigned to the experimental group of man-
aged, shared or integrated care, effects are not likely
to be large or impressive. Using disease-specific out-
come measures gives an opportunity to tap more
precisely intervention-related improvement in domains
of health, which may have been deteriorated due to
the disease where generic measures contain items
that are not likely to be linked to domains of health
status that may change due to the disease or handicap
of the patients in the study. Although the question of
whether instruments, that are tailored to the disease,
are superior to measures of general function in terms
of sensitivity to change, has not been settled definitely,
a growing number of studies indicate that disease-
specific measures seem to be more responsive than
generic measures w36, 42, 47, 51, 72–76x.
Effect size (ES) as indicator of
responsiveness
Mean differences in outcomes between baseline and
post-intervention of a test can be standardised to
quantify a care intervention’s effect in units of standard
deviation (SD). Consequently, standardising mean
change over time with a standard deviation allows
comparison of a particular intervention’s different out-
comes, independent of the measuring units. The
resulting statistical measure is known as effect size
(ES) index. In many evaluation studies, standardised
change over time in HRFS (ES) is used in compari-
sons of groups who were treated differently. This
method of expressing change scores in a so-called
effect size index seems to be an appropriate method
to estimate the magnitude of change over time in
before—after study designs.
The effect size index tells us something very different
from the p-value, which indicates the obtained proba-
bility of a Type I error in a test of statistical signifi-
cance. If a p-value is annotated as statistically
significant, rejecting the null-hypothesis does not imply
that the effect was important in any way nor does a
non-significant p-value indicate a trivial result w77–80x.
Criticism of statistical hypothesis testing has a long
history w81x, and even Jacob Cohen w15, 82x ‘‘played
a prominent role in the anti-hypothesis-testing charge’’
w83x. The adoption of a fixed level of significance may
lead to the situation in which two researchers obtain
identical intervention effects but obtain different p-
values (0.04 and 0.06) due to the effect of (slightly)
different sample sizes leading to different decisions.
Thus, p-values are confounded by the joint influence
of sample size and the effect size w84x and make the
rejection of the null-hypothesis not very informative.
Another criticism of null hypothesis testing is that it is
foolish to ask: ‘Are the effects of A and B different?’
‘‘They are always different—in some decimal place–
for any A and B’’ w85x. Since then, quantitative inves-
tigators in medical and social sciences have proposed
a variety of supplementary effect size indices, some
of which we will clarify. Reporting effect sizes without
appropriate statistical tests and associated p values
is misleading and potentially dangerous if the number
of observations that is required to detect a difference
has not been estimated by means of a power analysis.
Effect size statistics should be provided to supplement
statistical testing (not as a substitute for it), and only
when the outcome is sufficiently extreme from what
would have been expected on the basis of chance
(p-a).
It should be noted that during the debate on ‘signifi-
cance testing’, several vocal leaders in psychology
and education research called for the universal report-
ing and interpretation of empirically produced effect
sizes w86, 87x.
There are myriad estimates of effect size out of which
the researcher can make a choice w88x and the
question arises as to which of the effect size measures
‘that could be summoned up for a given problem
should a researcher report?’ w83, 84x The most elegant
solution for this problem would seem to be for authors
to include the sufficient statistics so that every reader
can compute whichever effect size index they believe
is best suited to the situation. Table 1 gives an
overview of responsiveness measures in repeated
measurement study designs.
Estimation of magnitude of
change
Effect size: a problematic statistic
For those researchers who are not conversant with
this method of estimating the amount of change over
time it is essential to know that in the last decade
various critical comments about Cohen’s work w16x
have been made. These include:
– there is no consensus on the ‘theoretical’ meaning,
or the conceptualisation of the effect size as an
outcome variable;International Journal of Integrated Care – Vol. 2, 17 December 2002 – ISSN 1568-4156 – http://www.ijic.org/
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Table 1. Formulas for responsiveness measures for change over time (Within-group standardised mean change)
Paired t statistic
¯¯ X1yX2
x SE
Effect size (1)
¯¯ X1yX2
xx SDpooled
Effect size (2)
¯¯ X1yX2
SDbaseline scores
Effect size (3)
¯¯ ¯¯ (X1yX2) y(X1yX2) treated subjects controls
SDpooled baseline
Standardised Response Mean (1)
¯¯ X1yX2
SDchange scores
Standardised Response Mean (2)
¯¯ X1yX2 improved subjects ()
SDchange scores improved subjects ()
Standardised Effect size
¯¯ X1yX2 improved subjects ()
SDbaseline improved subjects ()
Responsiveness index (1)
xxx M.C.I.D
SDchange scores stable subjects ()
Responsiveness index (2)
¯¯ X1yX2
SDbaseline stable subjects ()
Responsiveness index (3)
¯¯ X1yX2
SDchange scores stable subjects ()
Responsiveness coefficient
2 ¯¯ s (X1yX2)
22 ¯¯ s (X1yX2)qs error
Normalized ratio
¯¯ X1yX2 improved subjects ()
SDbaseline stable subjects ()
Relative efficiency statistic (t-statistic yt-statistic )2
measure 1 measure 2
Relative efficacy indexxxxx (ES yES ) = 100 2
pp b e s t
SEsstandard error of the difference x
where pooled for: N sN
22 (SD ) y(SD ) baseline outcome xx SDs baseline outcome y 2
Minimal Clinically Important Difference according to external criterion (i.e. the difference in change score between those who perceived xxx
no change and those who perceived little change) which is considered to be the minimal difference in change over time that patient’s perceive
as meaningful.
Magnitude of change over time is estimated for each scale by dividing the mean change by the pooled variance of change, according xxxx
to Cohen {154} denoted as ES . This relative efficacy statistic is computed by squaring the ratio obtained by dividing each scale ES p p
(numerator) by the scale having the largest ES (denominator). This statistic is then expressed as a percentage with respect to the best p
measure.
– there is no consensus on the mathematical way
to determine the magnitude of the difference
between scores gained on two different occasions:
researchers classify the extent of responsiveness
and magnitude with effect sizes using several
standard deviations (see Table 1);
– threshold values for ‘trivial’ (-0.20), ‘small’
(G0.20-0.50), ‘moderate’ (G50-0.80) and
‘large’ (G0.80) effects only apply to effect size 1
in Table 1.
How to give meaning to the magnitude of
change
Regarding the use of the notion of effect size in HRFS
research, several researchers have claimed that with-
out an external criterion, the estimated amount of
change measured by the effect size index can be
denoted as clinically important change w20, 21, 57,
58, 89x. Other researchers assume that an effect size,
estimated within a group of subjects, expresses the
measure’s ability to detect change over time (due to
an experimental intervention) w17–22, 57, 72x without
claiming that their effect size indicates that the instru-
ment is sensitive or responsive to clinically relevant
changes in the patients’ perceived health. When a
HRFS instrument is used as an outcome measure,
and the amount of change estimated with change
scores (or quantified by an effect size) is defined as
clinically relevant, the following question logically aris-
es: ‘What is meant by a clinically relevant change?’
w90, 91x Because patients and health professionals
differ in the preferences or perceived relevance that
they assign to particular aspects belonging to domains
of health-related functional status, several authors
have incorporated these perceptions or preferences
into health status instruments’ items and scales w5,
75, 89, 90, 92–95x to give more significance to the
term ‘relevant’. In this paper, we address the meth-
odological problems of quantifying change over timeInternational Journal of Integrated Care – Vol. 2, 17 December 2002 – ISSN 1568-4156 – http://www.ijic.org/
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with effect size indices and the risks of overestimation
and underestimation according to widely used thresh-
olds introduced some 30 years ago w16x.
How to quantify change in terms of effect size
Many evaluation studies have been conducted
that use different methods to estimate magnitude of
change over time in terms of Effect Size (ES). These
have indicated that there is no convincing evidence
that either method offers any apparent advantages w6,
74x. The literature shows that numerous quantitative
indices belonging to the family of effect sizes (ES)
w88x have been developed. However, there is no
consensus on how to declare a difference in terms of
standard deviation units. The interpretation of the
effect size is determined by the choice of the standard
deviation used to standardise the mean change over
time and, related to that, by the ready adoption of the
interpretation guideline as set by Cohen w16x. Several
effect size indices are used in HFRS and quality of
life research, which have in common that is ¯¯ X yX 12
divided by a standard deviation. The researcher’s
decision as to which SD he will take is either a well-
considered choice or one which is copied from well-
reputed colleagues and has no further justification.
However, in giving meaning to standardised mean
change in terms of ‘trivial’, ‘small’, ‘moderate’, or ‘large’
effects using the thresholds that Cohen w16x provided
us with some thirty years ago, it seems to have been
forgotten that these cut-off points were calculated with
the pooled standard deviation (SD ). Consequently, P
applying these thresholds for mean change scores
standardised with the standard deviation of the change
scores () , which is not equal to ¯¯ X yX ySD ty1 ty2 X1yX2
the pooled standard deviation (SD ), may lead to P
over- or underestimates of effects.
For his effect size (mean baseline scores minus mean
follow-up scores, divided by the pooled standard devi-
ation) Cohen came up with conventions for those
values that constitute a ‘trivial’ (ES-0.20), ‘small’
(ESG0.20-0.50), ‘medium’ (ESG0.50-0.80), and a
‘large’ effect (ESG80). However, for each of the effect
size and responsiveness indices from Table 1 (except:
T-Test, Normalized ratio, and relative- and efficacy
indices), these thresholds are used indiscriminately,
which may have contributed to the confusion in this
area w61x.
Effect size interpretation: the threat of internal
and external validity of (quasi) experimental
research by overestimation or underestimation
In the practice of health-related quality of life research,
most researchers remain primarily interested in the
statistical significance of the change in health-related
functional status or quality of life in pre post designs.
In combination with e.g. the T-test approach, substan-
tial effects can be detected w96–98x with an estimate
of effect size. If a p-value is annotated as statist-
ically significant, rejecting the null hypothesis does not
imply an effect of important magnitude; likewise, a
non-significant p-value does not indicate a trivial result
w77–80x, although some researchers implicitly deem
more important those results with smaller p-values.
In the last decade, however, a growing number of
longitudinal intervention studies are focussed on ques-
tions like ‘‘If the change between baseline and out-
come is statistically significant, what can we say about
the magnitude (or amount) of change over time that
has been detected? Can we interpret this difference
in terms of an important difference or as a relevant
(substantial) change?’’ To answer these questions,
the responsiveness i.e. the ability of quality of life
outcome measures to detect change over time, has
become crucial in the past decade. However, the
responsiveness estimation is neglected in many eval-
uation studies in which it could give information on
the importance of change due to intervention-related
effects supplementary to the statistical significance of
change over time (e.g. before and after intervention)
w99, 100x. Reporting effect sizes without appropriate
statistical tests and associated p-values is misleading
and potentially dangerous when the number of obser-
vations that is required to detect a difference has not
been estimated with a power analysis. Effect size
statistic should be provided to supplement (not as a
substitute for) statistical testing, and only then, when
the outcome is sufficiently extreme from what would
have been expected on the basis of chance (p-a).
Noteworthy in this respect is that in the field of
psychological research, editorial policy indicates that
‘‘until there is a real impediment to doing so, authors
should routinely present an effect size estimate along
with the outcome of a significance test’’ w84, 86, 87x.
Table 1 shows that several quantitative indices have
been developed that belong to the family of effect
sizes (standardized differences) each calculated with
a different denominator in the () formula, ¯¯ X1yX2ySD
for example, the SD of stable subjects, the SD of the
baseline assessment, the SD of the observed change
score (improved, stable subjects) etc. Obviously, there
is no consensus on how to declare a difference in
terms of standard deviation units. Only in a small
number of publications is this lack of consensus on
the most appropriate effect size indicator signalled
w13, 90, 101–104x.
Despite the fact that different opinions exist on the
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groups or the magnitude of change within groups,
researchers use the straitjacket of thresholds Cohen
provided us with some 30 years ago w16x. However,
these thresholds are taken for granted by many
researchers for every version of effect size index. With
regard to the correct use and interpretation of effect
size indices as estimates of intervention-related
magnitude of change, we must revisit some basic
assumptions:
– the ES is developed and elaborated by Cohen to
estimate power or the necessary sample size to
detect relevant change with the basic principle of
independent, equal size samples with common
within-population standard deviation ;
s
– in the case that this ES is used to calculate the
sample size needed to detect change in paired
samples or in a repeated measurement-design it
must be adjusted for correct use of Cohen’s power
tables and sample size tables. However, this
adjusted ES cannot be interpreted with Cohen’s
thresholds for effect size interpretation in evalua-
tion research;
Effect Size estimation with independent
(treatment vs. control) and dependent
observations (repeated measurement)
Independent samples
Cohen represented the effect size (ES) on some
dependent or outcome measure used in an experi-
ment in terms of the difference (using the symbol d9
to denote this ES) between the treatment and control
group expressed in units of common within-population
standard deviation (in samples this standard deviation
is estimated with the pooled standard deviation) as
follows:
wFormula Ax
¯¯ X yX Ž. treatment control
ESsd9
s
With this estimate of effect size, after analysing a wide
sampling of behavioural research, Cohen developed
his rules of thumb and reported that effect of 0.8
s
being on the large end of the range, 0.5 was the
s
medium, and 0.2 was at the small end of the range
s
w105x.
Dependent samples or paired observations
The difference or change in matched observations
within subjects is standardised by the common within-
population , according to Cohen’s w16x p. 13, but due
s
to the removal of the variation in many extraneous
characteristics of the subjects, the index must be
adjusted w16x, dividing d9 by 6(1yr). Cohen used the
symbol d to denote this adjusted ES (in evaluation
research often labelled as Standardized Response
Mean).
wFormula Bx
d9
ds
y(1yr)
d9seffect size for independent samples
dsadjusted effect size
rscorrelation between baseline and outcome
This 6(1yr) – correction of the denominator of for-
mula A is necessary for a proper use of power and
sample size tables since these assume 2(ny1)
degrees of freedom where, in the case of paired
observations, only ny1 are actually available w16x.
This consequence for power and sample size esti-
mation is something different from the use of the effect
size d in evaluating efficacy of a new intervention in
terms of amount of change in health status, which
was not the aim of Cohen’s work.
Overestimation or underestimation of effect by
using Cohen’s thresholds for SRM
When effect sizes are calculated as the standardized
difference in mean score to evaluate the magnitude
of difference in HFRS, for example, between an inter-
vention group (interdisciplinary or integrated care and
a control group, formula wAx should be used. The
effect size can be calculated by pooling the estimates
(pooled standard deviation) derived from sample data.
In contrast to this independent sample case, effect
sizes are also used in evaluation studies (pre- post
study designs) as estimates of the responsiveness
or change over time within groups. Effect sizes are
also in these study designs used to give meaning to
change over time in terms of ‘trivial’ (ES-0.20),
‘small’ (ESG0.20-0.50), ‘moderate’ (ESG0.50
-0.80) or ‘large’ (ESG0.80) change. Cohen w16x
introduced this ‘matched pairs’ effect size, which was
later renamed the standardised response mean
(SRM) by Liang et al. w106x to avoid confusion con-
cerning other effect size indices. However, several
researchers seem to have adopted the idea that every
standardised difference is subject to Cohen’s defini-
tions of trivial, small, moderate and large effect. Such
a belief could lead to misinterpretations in studies
focussing on intervention-related outcome in pairedInternational Journal of Integrated Care – Vol. 2, 17 December 2002 – ISSN 1568-4156 – http://www.ijic.org/
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Table 2. The conversion of an effect size calculated with the pooled SD (ESP) of 0.42 into an SRM with correlation coefficients ranging from
0.00–0.90
Corr. 0.00 00.10 0.20 0.30 0.40 0.50 0.60 0.65 0.70 0.80 0.86 0.90
(0.42y62)
6(1yr) 0.30 0.31 0.33 0.36 0.38 0.42 0.47 0.50 0.54 0.66 0.79 0.94
samples since these cut-off points of the magnitude
of the difference were not established as a rule of
thumb with the effect size d (dependent samples) but
with the index d9 (independent samples). Thus, we
argue that Cohen’s thresholds are based on the
assumption of common within-standard deviation (with
matched pairs sample data we use the raw within-
group pooled SD), resulting in an effect size we
annotate as ES . Consequently, in matched pairs P
studies these thresholds cannot be used interchange-
ably for the SRM due to the role of the correlation
between repeated measures or between scores from
paired samples. In this part of the article the attention
is focussed on the standardized change in mean score
between two points in time within a single group,
estimated with the within-group effect size. In relation
to the use of Cohen’s rule of thumb for effect size
interpretation, we evaluate the consequences of the
calibration of the SRM with the ES and the role of P
the correlation between pre- and post-test scores.
To investigate how serious discrepancies can appear
in effect size interpretation we first elaborate a theor-
etical example and used a sample of studies to
evaluate the seriousness of these differences in prac-
tice. To evaluate the seriousness of the discrepancies
between SRM and ES , the correlation of the subject’s P
repeated measurements was needed. Empirical data
were collected for the purpose of secondary analysis
to draw conclusions in terms of the relative size of the
SRM to the ES in relation to the size of the correla- P
tion. Applying Cohen’s thresholds (which are based
on the pooled estimate of effect) to interpret the SRM
on the one hand may lead to similar results or subtle
and trivial differences, but on the other hand also to
meaningful shifts in classification of the amount of
estimated change. In this article we analysed 148
SRMs interpreted using Cohen’s rule of thumb and
compared these SRMs with Cohen’s ES calculated P
with the same data. Furthermore, we calculated for
the range of the correlation coefficient (r) 0.01 to 0.99
the SRM adjusted for Cohen’s cut-off points 0.20, 0.50
and 0.80 of the pooled effect size.
To study the consequences of the impact of the
association or correlation between repeated meas-
ures, we restrict the analysis to two effect size indices
suitable for the evaluation and interpretation of mag-
nitude of change over time (or responsiveness) within
one group, namely the SRM and the ES . P
wFormula Cx
¯ Xchange ES s p SD pooled ()
The ES introduced by Cohen was made comparable P
to the SRM where the (SD ), is used as the X-change score
denominator in which, as we will demonstrate below,
the correlation between baseline and outcome scores
is involved.
The SRM is the ratio between the mean change score
and the variability (the standard deviation) of that
change score within the same group.
wFormula Dx
¯ Xchange SRMs
SD Xchangeyscore ()
One of our purposes was to get an indication of how
the SRM varies in accordance with the size of the
correlation between pre- and post-test scores when
the correct pooled effect size estimate is used. An
example may illustrate the role of r, the correlation of
a person’s health status measurements over time:
In a study in which the outcome of an intervention
was evaluated with a HRFS measure, and in the case
of improvement, a lower mean score after intervention
was hypothesised. The investigator finds at baseline
a mean score of 11.12 with a standard deviation of
4.43 and a mean score of 9.16 (SD: 4.88) at follow
up. The estimate of the common within-stan-
dard deviation, which is the square root of
(SD ) q(SD ) y2), thus 4.66, and the pooled 22
baseline outcome
effect size d9 (ES ) is then calculated as follows 0.42 P
(11.12–9.16y4.66). Before we compare the ES and P
SRM in relation to the correlation between repeated
measurements, we must solve the problem of the
equation of both formulas C and D. According to
Cohen, the difference between means for dependent
samples is standardised by a value ‘‘which is 62 (1yr)
as large as would be the case were they independent’’
w16x.
From equation A4 in the appendix (d9y62)y6(1yr) is
equivalent to the SRM and alternatively SRM * 6 2*International Journal of Integrated Care – Vol. 2, 17 December 2002 – ISSN 1568-4156 – http://www.ijic.org/
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Table 3. Comparison of four Standardised Response Means cali-
brated into Cohen’s pooled effect size index (ES ). Effect Size d9 p
(ES ) p
Trivial Small Moderate Large
SRM 0–-0.20 G0.20–-0.50 G0.50–-0.80 G0.80
Trivial 2
Small 3 4
Moderate 9 8
Large 8 6
Table 4. Similarities and differences between the Standardised Response Mean (SRM) and pooled effect size d9 (ES ) interpreted using P
Cohen’s thresholds (ns148)
ESpooled ES-0.20 ESG0.20-0.50 ESG0.50-0.80 ESG0.80 Total
Trivial effect Small effect Medium effect Large effect
SRM
-0.20 43 2 45
G0.20-0.50 6 35 2 43
G0.50-0.80 11 13 1 25
G0.80 12 23 35
Total 49 48 27 24 148
SRM indices interpreted by authors according to Cohen’s thresholds for ESpooled
6(1yr) is equivalent to d9 and both indices will vary
with the size of r.I nTable 2, we have elaborated the
hypothetical example in which this effect size d9
(ES )s0.42, is transformed into the SRM for a series P
of values of r. Both effect sizes are equal in the case
that rs0.50):E Ss(0.42y62)y6(1y0.50)sSRM, and P
the SRM for rs0.50 is then (0.42y1.41)y0.71s0.42.
In Table 2 it is shown that the SRM gets larger for
larger values of r. For example, an effect size of 0.42
indicating ‘small effect’ corresponds with a ‘medium
effect’ (SRMs0.50) if the correlation between the
repeated measurements is approximately 0.64. This
small effect estimated with the ES corresponds with P
a ‘large effect’ (SRMG0.80) if this correlation is
approximately 0.86.
If we take Cohen’s original work w16x as being valid,
we will have to rectify interpretations of the meaning
of the estimated magnitude according to the results
from this analyses. In previous work, we published
two studies w55, 71x in which 40 Standardised
Response Mean indices were interpreted according to
Cohen’s thresholds for pooled estimates of standard
deviation (ES ) out of which 20 turned out to be p
overestimations or underestimations of intervention-
related effect (Table 3).
In another study w107x, we analysed this problem
using results from other researchers. This secondary
analysis of data from other studies revealed that 23%
of the estimated effect sizes did not fall in the same
magnitude of change category according to the
Cohen’s thresholds (Table 4).
To avoid invalid interpretations in the evaluation of
responsiveness with SRM index we have, for every
value of the correlation between baseline and follow-
up score, calculated the corresponding ES ’s for P
Cohen’s thresholds of 0.20ssmall, 0.50smedium,
and 0.80slarge. Indices that lie within the interval that
corresponds with these thresholds are not depicted.
To classify the magnitude of change estimated with
the SRM more precisely, this effect size index is
adjusted for every value of the correlation coefficient
(r) between baseline and follow-up assessments and
brought into line with Cohen’s thresholds for effect
size. Figure 1 shows that SRMs of 0.20, 0.50 and
0.80, don’t deviate after calibration with Cohen’s ESP
taken as the original standard, when r s0.50. How-
ever, an SRM of 0.20 must be tagged as trivial effect
as long as the correlation coefficient ranges from r
s0.01 to r s0.49. With large corresponding correla-
tion coefficients (rs0.92) a small SRM of 0.20 must
be tagged as moderate (0.20y62y61–0.92s0.50) or
(rs0.97) large (0.20y62y61–0.97s0.80). The class
midpoint 0.35 of the ‘small effect’ range of effect (not
depicted) has to be classified as moderate or large
effect with correlation coefficients of 0.76 (0.35y62y
61–0.76s0.50) and 0.91 (0.35y62y61–0.91s0.80),
respectively.
SRMs of 0.80 has to be tagged as ‘moderate’ effect
(ESs0.58–0.79) if the correlation ranges from
rs0.01 to 0.49. The SRMG0.80 cannot drop below
the cut-off points of small and trivial ES due to the
correlation magnitude between baseline and outcome
measurements. ‘Moderate’ effect (SRMs0.50) must
be tagged as ‘small’ if the correlation between repeat-
ed measures is below 0.49 and has to be classified
as ‘large’ (ESG0.80) in case of rs0.81. The class
midpoint 0.65 (not depicted) of the ‘moderate effect’International Journal of Integrated Care – Vol. 2, 17 December 2002 – ISSN 1568-4156 – http://www.ijic.org/
11 This article is published in a peer reviewed section of the International Journal of Integrated Care
Figure 1. Cohen’s threshold’s for effect size SRM corrected for the size of the correllation coefficent between repeated measurements.
range of effect must be valued as ‘small’ with a rs0.14
(0.65y62y61–0.14s0.49).
In contrast with the fixed threshold values 0.20, 0.50
and 0.80 in Figure 1, in the analysis of 148 effect size
estimates from which the correlation of a person’s
health status measurements over time was calculated,
we found SRM values ranging from 0.04 to 2.42 w107x.
Correlation coefficients ranged from 0.08 to 0.89 and
70% of the 148 coefficients were larger than 0.50.
Overestimates of effect size are easily estimated. For
example: an SRM of 0.85 interpreted by the research-
er as large effect, changed into a moderate effect
according to Cohen’s thresholds, due to a correlation
of 0.12 between repeated measurements
Conclusion – Discussion
Thus, the SRM interpretation of effect magnitude with
the thresholds Cohen with the ES calculated on the p
same data (transformation of the same mean change
over time into units of pooled standard deviation) may
result in dramatic differences (23–50% of the SRM
indices are overestimated). Unfortunately, we still
have no algorithm for effect size indices calculated
with the standard deviation from baseline scores or
from change scores in stable subjects according to an
external criterion. Furthermore, even in a situation
where we are able to reliably interpret effect size, we
cannot differentiate between a ‘large’ and ‘very large’
effect since the cut-off point for large has a theoretical
range from ES 0.80 to infinite. However, Hopkins’
w108x Likert-scale approach is able to give meaning
to the extension of the scale to the level above large
for Cohen’s effect size statistic: ESs0–-0.20 trivial
effect; ESG0.20–-0.60 small effect; ESG 0.60-1.20
moderate effect; ESG1.20–-2.0 large effect;
ESG2.0–-4.0 very large and ESG4.0–` is consid-
ered to be ‘nearly perfect’. In addition, to thresholds
for effect magnitudes, Hopkins elaborated Cohen’s
thresholds for correlation coefficients, relative risks
and odds ratio. Despite this promising attempt to
proceed with a more complete scale of effect magni-
tude, further research will need to provide empirical
evidence for the external validity of this new rule of
thumb for effect size interpretation irrespective of
health status measure and research designs.
Ever since Jacob Cohen wrote his well-known book
w16x, the effect size has been a problematic parameter
in evaluation research, and several promising alter-
natives (for example, the ‘‘Reliable Change Index’’),
have been developed w109x, improved and criticised
w35, 110–113x. In future studies statistical computer
programmes may be able to give the researcher
additional information on some intervention effect indi-
ces (notwithstanding the fact that no consensus exists
on a method for signifying the magnitude of change
within and between experimental and control groups
that is meaningful in particular intervention contexts).
Nevertheless, implementing effect sizes standard in
the representation of statistical results may require
researchers to change long-held patterns of
behaviour.
The values used in effect size classification for differ-
ence between means as small, medium, and large
was arbitrary but seemed reasonable, Cohen stated
some 30 years ago. In the debate over which stan-
dardizing unit of the difference one should take in a
within-group situation, we propose that estimating the
magnitude of change by using either the SD of the
change score or the pooled SD is preferable to the
use of the SD at baseline as proposed by Kazis et al.
w114x, although the SRM must be adjusted to make
correct use of Cohen’s thresholds when magnitude of
change over time is estimated in evaluation research.International Journal of Integrated Care – Vol. 2, 17 December 2002 – ISSN 1568-4156 – http://www.ijic.org/
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These thresholds of Cohen are now being cited with-
out distinguishing between the unit by which the
assessed change over time is standardised. This is
surprising since there is unequivocally no doubt that
his rule of thumb was derived from the pooled SD as
the estimate of the common within variance. More-
over, routine action in calculating effect sizes may
have led to a reduced awareness of factors originally
considered only in the calculation of power and sam-
ple size. For instance, the calculation of power of the
detected change or difference without using the infor-
mation of r can lead to the wrong inferences w16x.
In evaluation research on treatment-related quality of
life, researchers seem to overlook the fact that, in
assessing change over time within one subject, the
experimental technique of ‘self-matching’ reduces the
proportion of the total variance due to extraneous
variables not related to the treatment or intervention
per se w115x.
We may conclude that the rule of thumb proposed by
Cohen can induce differences in the interpretation of
the size of estimated effects. At present it does not
appear to us that a single set of rules that is unequiv-
ocal or normative at some level is available. We have
begun to explore alternative methods in effect size
estimation and have assessed the interrelation
between two effect sizes as estimates of magnitude
of change over time within groups.
As we have demonstrated, errors can easily be made
and different interpretations of the magnitude of
detected change may occur. In analysing the data
from our sample of published studies on change over
time in health-related quality of life, we saw meaningful
shifts in magnitude of detected change in relation to
the size of the correlation between pre- and post-test
scores. In this article we have attempted to draw the
attention to the problem of over- or underestimation
of effect sizes when the Standardized Response Mean
is used. Studies in which the mean change over time
is standardized with the SD according to Kazis baseline
et al. w114x should report the ES to show that the p
results were not dependent on the choice of denomi-
nator in the d-index formula.
Due to their increasing appearance, it is important that
all aspects of estimating the magnitude of change be
inspected. One of these aspects is the consequence
of the hidden role of the correlation coefficient between
repeated measurements, which increases the risk of
incorrect conclusions. This initial effort may provide a
moderate step toward the development of a precise
and useful index in quality of life assessment in clinical
trials.
Recommendations for practice and
research
So long as no consensus reached on standards for
evaluating, using and interpreting effect size estimates
of intervention-related change in evaluation research,
there is an important need to develop uniform and
widely accepted criteria to give meaning to the size of
an effect. This lack of precision is not only relevant
when evaluating intervention-related change within
and between groups, but, even more important in the
estimation of power in the planning phase of a trial.
Standardisation of effect size interpretation needs
reference ranges of health-related functional status
assessed with population surveys. Furthermore, lon-
gitudinal research is needed to discriminate between
changes in HRFS over time in a sample drawn from
the general population, with change in a sub-sample
of chronically ill patients. In other words, with knowl-
edge about a reference range of an indicator of health-
related functional status in the general population, we
can recognise that there are differences. Furthermore,
with a longitudinally assessed estimate of autonomous
change in the same sample, we will be able to better
understand the meaningfulness of intervention-related
effects.
In studies on the measurement of health-related qual-
ity of life and HRFS, effect sizes (ES) have been used
as surrogates for clinically relevant change when
change over time in outcome was substantial. How-
ever, ES do not provide a complete understanding of
the meaningfulness of the observed change. Patients
have to perceive a change in the performance of daily
activities in order to rate the direction and degree of
change; moreover, even when this perceived change
is small in magnitude, it may still be perceived as a
significant one by the patient. According to Osoba
w116x, the significance of change as perceived by the
subject ‘should be of paramount consideration’ in
future attempts to define the meaningfulness of
change in HRFS or health-related quality of life. The
development of multi-item transition measures may
cover change in the relevant underlying domain more
representatively w107, 117x. Therefore, we suggest
that measures that assess more concrete aspects of
the patient’s HRFS will provide greater accordance
between serial and transition measures of change.
However, when a patient rates a reduction in (for
example) difficulty in climbing stairs, as ‘large’, it does
not necessarily imply that a patient will view this
subjectively significant change as being important.
Future areas of research aimed at quantification of
meaningful change in HRFS should also include the
importance patients assign to that change, even if itInternational Journal of Integrated Care – Vol. 2, 17 December 2002 – ISSN 1568-4156 – http://www.ijic.org/
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is experienced as being small. One piece of research
has produced examples that seem promising exten-
sions of transition questions. In this approach, the
respondent rates the direction and the degree of
perceived change by a assigning a value that has
meaning to the respondent for the experienced
change, as well as by rating the degree of importance
the respondent assigns to perceived change. In eval-
uation of intervention-related change in evaluation
studies, the importance assigned to the small improve-
ment in one item of a domain of HRFS may outweigh
a moderate deterioration in another item belonging to
the same domain.
Finally, the following are key issues in the debate on
methods for estimating clinically important change:
Significance of intervention effects: significance to
whom w93x who is to say what is important? w90x and
‘‘ask patients what they want’’ w94, 118–120x have
increasingly become apparent. To give clinically rele-
vant meaning to change scores gained on two differ-
ent points in time using HRFS instruments, several
investigators suggest that the current approaches
could be improved by taking more explicit account of
patients’ perceptions and expectations. A new para-
digm is incorporating individual patient perspectives,
expectations and preferences with respect to the
effects of (innovative) interventions in the outcome
measures. With scoring systems based on individual-
ised measures such as the so-called Goal Attainment
Scale (GAS) or Patient Specific Index (PCI), each
patient essentially receives his or her ‘own instrument’
and these instruments seem to show an improved
sensitivity to change in health-related functional status
when compared with conventional methods w75, 92,
95, 121–125x.
Methodological studies focussed at improving the lon-
gitudinal validity or responsiveness of health outcome
measurement should be aimed at supporting, health
professionals, investigators and administrators in the
understanding and critical evaluation of the appropri-
ateness of health status measures and understanding
of methods in estimating and interpreting change in
patient-assessed health outcomes. Health profession-
als increasingly stress that in the realisation of effec-
tive care and expected outcome of planned change in
the process of care delivery, patients’ preferences are
essential sources of information. The operationalisa-
tion of the patient’s perception of the severity of
limitation in domains of health-related functioning, or
operationalisation of individual preference or weighted
relevance of items of health-related functional status
measures is still in its infancy. However, for health
administrators and decision-makers, investigation into
the validity of patient-specific HRFS instruments used
to evaluate the outcomes of innovative and care,
standardisation of methods is required. HRFS instru-
ments cannot be used in the evaluation of treatment
and care without a valid way of ascertaining what
change in measured difference scores means.
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